Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
humanized mouse model
immune checkpoint blockade
nasopharyngeal carcinoma
patient-derived xenografts
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Apr 2020
22 Apr 2020
Historique:
received:
22
03
2020
revised:
13
04
2020
accepted:
17
04
2020
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
26
4
2020
Statut:
epublish
Résumé
Immune checkpoint blockade (ICB) monotherapy shows early promise for the treatment of nasopharyngeal carcinoma (NPC) in patients. Nevertheless, limited representative NPC models hamper preclinical studies to evaluate the efficacy of novel ICB and combination regimens. In the present study, we engrafted NPC biopsies in non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain-null (NSG) mice and established humanized mouse NPC-patient-derived xenograft (NPC-PDX) model successfully. Epstein-Barr virus was detected in the NPC in both NSG and humanized mice as revealed by Epstein-Barr virus-encoded small RNA (EBER) in situ hybridization (ISH) and immunohistochemical (IHC) staining. In the NPC-bearing humanized mice, the percentage of tumor-infiltrating CD8
Identifiants
pubmed: 32331230
pii: cancers12041025
doi: 10.3390/cancers12041025
pmc: PMC7225949
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Medical Research Council Singapore, CS-IRG
ID : CIRG19may-0051
Organisme : VICTORY Programme
ID : NMRC/OFLCG/003/2018
Organisme : Senior Clinician Scientist Award, CSA
ID : NMRC/CSASI16nov006
Organisme : National Medical Research Council Singapore
ID : NMRC/TCR/015-NCC/2016
Organisme : National Research Foundation Singapore Fellowship
ID : NRF-NRFF2017-03
Organisme : NRF-ISF joint grant
ID : NRF2019-NRF-ISF003-3127
Organisme : A*STAR IAF-PP
ID : H18/01/a0/022
Références
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Cell Mol Immunol. 2012 Jan;9(1):11-9
pubmed: 22020068
Mol Cells. 2016 Feb;39(2):77-86
pubmed: 26831452
Cancer Lett. 2014 Mar 1;344(1):1-12
pubmed: 24157811
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Exp Clin Cancer Res. 2018 Sep 20;37(1):233
pubmed: 30236142
Int J Cancer. 2015 Feb 1;136(3):678-87
pubmed: 24947555
Int J Cancer. 1999 Sep 24;83(1):121-6
pubmed: 10449618
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
Sci Rep. 2018 Oct 26;8(1):15855
pubmed: 30367142
Vaccines (Basel). 2016 Jun 24;4(3):
pubmed: 27348007
Cell Death Dis. 2015 Jun 18;6:e1792
pubmed: 26086965
Int J Cancer. 1989 May 15;43(5):936-9
pubmed: 2714899
F1000Res. 2018 Nov 21;7:
pubmed: 30519454
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
J Invest Dermatol. 2014 Oct;134(10):2551-2561
pubmed: 24751730
Gut. 2016 Oct;65(10):1744-53
pubmed: 26149491
N Engl J Med. 2019 Sep 19;381(12):1124-1135
pubmed: 31150573
Nat Rev Immunol. 2007 Feb;7(2):118-30
pubmed: 17259968
Immunity. 1994 Sep;1(6):447-56
pubmed: 7895156
Arch Immunol Ther Exp (Warsz). 2018 Aug;66(4):245-266
pubmed: 29411049
J Immunother Cancer. 2017 Feb 21;5:18
pubmed: 28239471
Int J Cancer. 2008 Nov 1;123(9):2105-12
pubmed: 18688856
Cancer Res. 2015 Sep 1;75(17):3466-78
pubmed: 26113085
Science. 2004 Apr 2;304(5667):104-7
pubmed: 15064419
Front Immunol. 2017 Aug 02;8:829
pubmed: 28824608
Blood. 2005 Sep 1;106(5):1565-73
pubmed: 15920010
J Immunother Cancer. 2015 Apr 21;3:12
pubmed: 25901284
Int J Cancer. 1999 Aug 20;84(4):396-9
pubmed: 10404092
Trends Immunol. 2018 Sep;39(9):748-763
pubmed: 30077656
Gut. 2018 Oct;67(10):1845-1854
pubmed: 29602780
Cancer Res. 1989 Dec 1;49(23):6752-7
pubmed: 2479472
Cancer Res. 1988 May 15;48(10):2858-66
pubmed: 2452013
Mol Cancer. 2015 Jun 11;14:119
pubmed: 26062742
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893937
J Leukoc Biol. 2013 Jul;94(1):41-53
pubmed: 23667165
Lancet Oncol. 2018 Oct;19(10):1338-1350
pubmed: 30213452
J Cancer Res Clin Oncol. 2015 Apr;141(4):767
pubmed: 25672952
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Ann Diagn Pathol. 2018 Dec;37:12-19
pubmed: 30218928
J Virol. 2019 Jan 17;93(3):
pubmed: 30429352
Nat Rev Cancer. 2016 Dec;16(12):759-773
pubmed: 27687979
Mol Cancer. 2010 Jan 10;9:4
pubmed: 20064222
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21783-8
pubmed: 19966223
Semin Cancer Biol. 2012 Apr;22(2):117-26
pubmed: 22311401
J Natl Cancer Inst. 2019 Mar 26;:
pubmed: 30912808
Brief Funct Genomics. 2019 Mar 22;18(2):99-106
pubmed: 29554204
J Clin Oncol. 2018 May 10;36(14):1412-1418
pubmed: 29584545
J Immunother Cancer. 2015 Dec 15;3:42
pubmed: 26674611
Nat Commun. 2018 Nov 7;9(1):4663
pubmed: 30405107
Int J Cancer. 2018 Jun 15;142(12):2558-2566
pubmed: 29377121
J Immunol. 2012 Dec 1;189(11):5223-9
pubmed: 23089398
Am J Clin Oncol. 2018 Dec;41(12):1204-1210
pubmed: 29672367
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Nat Rev Cancer. 2016 Dec;16(12):789-802
pubmed: 27687982
J Clin Oncol. 2017 Dec 20;35(36):4050-4056
pubmed: 28837405
Front Immunol. 2019 Sep 06;10:2083
pubmed: 31555290
Mamm Genome. 2019 Jun;30(5-6):123-142
pubmed: 30847553
Int J Cancer. 1991 Apr 22;48(1):57-61
pubmed: 1826899
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Oncotarget. 2016 Mar 15;7(11):13060-8
pubmed: 26918337
Chin Clin Oncol. 2016 Apr;5(2):22
pubmed: 27121882
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7
pubmed: 20615947
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Int J Cancer. 1988 Oct 15;42(4):599-606
pubmed: 2971626
Oncoimmunology. 2017 Apr 27;6(5):e1312240
pubmed: 28638740
Int J Cancer. 1980 Aug;26(2):127-32
pubmed: 6259064